What happened with COO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Most of The Cooper Companies' revenue comes from CooperVision, which makes contact lenses for people who need vision correction. Wearers replace these lenses daily or on two-week or monthly schedules, creating an ongoing need for replacements. Biofinity is its highest-grossing product; MyDay and clariti 1 day are its daily disposable brands.
Its other business, CooperSurgical, sells products and services through medical offices, hospitals, surgical centers and fertility clinics, and also directly to consumers. It supplies clinics with equipment and consumables for in vitro fertilization, alongside donor eggs and sperm, genetic testing and frozen storage services. Its women's-health business includes medical devices, the Paragard hormone-free contraceptive IUD and newborn cord-blood and cord-tissue storage. Office and surgical offerings generate more revenue than fertility offerings.
The business depends on reliable manufacturing and access to materials, some of which come from sole suppliers. Its medical devices require regulatory clearance or approval before sale and may be marketed only for authorized uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cooper’s results depend mainly on contact-lens demand, but its fertility business also hinges on IVF activity and competition from Vitrolife Group, which is missing from this list.
Alcon competes globally with CooperVision for wearers buying spherical, toric and multifocal contact lenses, so its lens business reflects both shared demand and rivalry for sales. Watch its contact-lens performance rather than total sales, which also include eye-surgery and ocular-health products.
Bausch + Lomb competes with CooperVision for consumers buying soft and specialty contact lenses, making lens demand and replacement habits relevant to both. Watch its contact-lens products more closely than its broader Vision Care revenue, which also includes other consumer eye-care products.
Johnson & Johnson Vision Care competes directly with CooperVision for wearers buying spherical, toric and multifocal contact lenses. Its contact-lens product news is the relevant signal for Cooper, especially in toric and multifocal lenses, where CooperVision’s fiscal 2025 sales growth came primarily from Biofinity and MyDay.
Bausch Health competes with CooperVision through its approximately 88%-owned Bausch + Lomb business, which sells contact lenses to wearers, so this largely repeats the operating exposure shown in Bausch + Lomb’s row. Watch that business’s silicone-hydrogel lens products rather than Bausch Health’s wider drug and aesthetic-device sales.
The Cooper Companies, Inc. earningsThis company
Cooper's report will show whether its contact-lens business keeps growing and whether fertility and women's-health sales growth is turning into more operating income.
Read sales growth alongside operating income for both businesses. Within CooperVision, watch toric and multifocal lenses against sphere and other products; within CooperSurgical, compare office and surgical products with fertility. Growing sales with improving operating income would show demand is translating into stronger profitability. Slower sales or weaker operating income would show that growth is fading or costs are absorbing it.
